



Practitioner's Docket No. MPI00-418P1RDV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rosana K-Libermann
Application No.: 10/713,345 Group No.: 1652
Filed: November 14, 2003 Examiner: N/A
For: 47174, A NOVEL HUMAN GLYCOSYLTRANSFERASE AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

(1) a final action under Section 1.113,

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"
Mailing Label No. _____

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker

(type or print name of person certifying)

Date: February 18, 2004

***WARNING:** Each paper or fee filed by "Express Mail" *must* have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will *not* be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-418P1RDV1M

- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

FEE PAYMENT

☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

METHOD OF PAYMENT OF FEE

- ☐ Attached is a check in the amount of \$ _____.
- ☐ Charge Account No. 501668 in the amount of \$0.00.
- ☐ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

February 18, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sibussat
Tracy M. Sibussat
Attorney/Agent for Applicant
Reg. No. 50,609
75 Sidney Street
Cambridge, MA 02139
Telephone: (617) 374-7679
Facsimile - (617) 551-8820

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2	Application Number	10/713,345
-------	---	----	---	--------------------	------------

Filing Date	November 14, 2003
First Named Inventor	Rosana K-Libermann
Group Art Unit	1652
Examiner Name	N/A
Attorney Docket Number	MPI00-418P1RDV1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	AH	Altschul et al, J. Mol. Biol., 1990, 215:403-410	
	AI	Altschul et al, Nucleic Acids Res., 1997, 25(17): 3389-3402	
	AJ	International Human Genome Sequencing Consortium, <u>Initial Sequencing and Analysis of the Human Genome</u> , Nature 1, Vol 409, 15 Feb 2001, www.nature.com	
	AK	Karlin et al., Proc. Natl. Acad. Sci. USA, 1990, 87(6):2264-2268	
	AL	Karlin et al., Proc. Natl. Acad. Sci. USA, 1993, 90(12):5873-5877	
	AM	<u>Molecular Cloning -- A Laboratory Manual</u> , 1989, 2 nd Edition, Sambrook et al. (eds.), Cold Spring Harbor Laboratory Press (Table of Contents only)	
	AN	Myers et al., CABIOS, 1988, 4:11-17	
	AO	Sonnhammer et al., Proteins, 1997, 28(3): 405-420	
	AP	The Human Genome <u>The Sequence of the Human Genome</u> , Science, Vol 291, 16 Feb 2001 www.Sciencemag.org	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/713,345
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	November 14, 2003
		First Named Inventor	Rosana K-Libermann
		Group Art Unit	1652
		Examiner Name	N/A
(use as many sheets as necessary)		Attorney Docket Number	MPI00-418PIRDVIM
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	AQ	Weintraub et al., <u>Trends in Genetics</u> , January 1985	
	AR	Shinya Toba, et al., "Brain-Specific Expression of a Novel Human UDP-GalNAc: Polypeptide N-Acetylgalactosaminyltransferase (GalNAc-T9)," <i>Biochemica et Biophysica Acta</i> , Vol. 1493, (2000), pgs 264-268	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.